A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer
Authors:
- Janice CowdenJCJanice Cowden
Open Access
- 1 September 2021
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (30) , 3911-3924
Abstract
Sacituzumab Govitecan (also known by the brand name TRODELVY®) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short. Metastatic breast cancer means the ...Keywords
Funding Information
- Gilead Sciences, Inc